Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Business & Industry
- Amgen and Adaptive Biotechnologies announce strategic partnership to develop a therapeutic to prevent or treat COVID-19
- First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
- Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services
- Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
- Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts
Research & Development
- Possible coronavirus drug identified by Australian scientists
- Clues to COVID-19 coronavirus's vulnerability emerge from an antibody against SARS
- New guidelines on caring for ICU patients with COVID-19
- FDA approves first plasma therapy for Houston Methodist COVID-19 patient
- Experimental AI tool predicts which COVID-19 patients develop respiratory disease
- Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)
- Singapore modelling study estimates impact of physical distancing on reducing spread of COVID-19
Conferences & Events
- Pre-Filled Syringes West Coast 2021
- Pre-Filled Syringes East Coast Conference 2020
- SMi's 4th Annual Pharmaceutical Microbiology West Coast
- SMi's 20th Annual Pain Therapeutics Conference 2020
- SMi's 3rd Annual Pharmaceutical Microbiology East Coast
- SMi's 22nd Annual Superbugs & Superdrugs Conference 2020
- SMi Presents the 3rd Annual Conference: Injectable Drug Delivery 2020
Regulatory Affairs
- FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19
- FDA Continues to Accelerate Development of Novel Therapies for COVID-19
- The FDA is facilitating access to convalescent plasma collected from recovered COVID-19 patients
- FDA continues to facilitate development of COVID-19 treatments
- FDA and FTC warn seven companies selling fraudulent products that claim to treat or prevent COVID-19